ImmunoCellular Therapeutics Ltd  

(Public, NYSEMKT:IMUC)   Watch this stock  
Find more results for NYSEAMEX:IMUC
-0.006 (-2.52%)
Feb 5 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.22 - 0.23
52 week 0.21 - 0.72
Open 0.22
Vol / Avg. 193,380.00/369,977.00
Mkt cap 20.27M
P/E     -
Div/yield     -
EPS -0.12
Shares 90.31M
Beta 0.87
Inst. own 13%
Mar 7, 2016
Q4 2015 ImmunoCellular Therapeutics Ltd Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Feb 8, 2016
ImmunoCellular Therapeutics Ltd at Biotechnology Industry Organization (BIO) CEO & Investor Conference - 2:00PM EST - Add to calendar
Dec 3, 2015
ImmunoCellular Therapeutics Ltd at PR Newswire and BetterInvesting (NAIC) Investor Conference
Nov 24, 2015
ImmunoCellular Therapeutics Ltd to Discuss ICT-107 Program - Webcast
Nov 16, 2015
ImmunoCellular Therapeutics Ltd Extraordinary Shareholders Meeting
Nov 10, 2015
Q3 2015 ImmunoCellular Therapeutics Ltd Earnings Call - Webcast
Nov 10, 2015
Q3 2015 ImmunoCellular Therapeutics Ltd Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -42.63% -34.66%
Return on average equity -48.96% -37.69%
Employees 4 -
CDP Score - -


23622 Calabasas Rd Ste 300
CALABASAS, CA 91302-1672
United States - Map
+1-818-2642300 (Phone)
+1-818-2245287 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company's cancer immunotherapies targets cancer stem cells (CSCs). Its product candidates include ICT-107, which completed phase II testing, and also a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. ICT-107, the Company's lead product candidate, is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. In addition to ICT-107, the Company develops other therapeutic DC vaccines, including ICT-140 for ovarian cancer and ICT-121 for recurrent GBM. ICT-140 targets seven tumor-associated antigens expressed on ovarian cancer cells. ICT-121 specifically targets CD133, a CSC marker that is overexpressed in a variety of solid tumors, including ovarian, pancreatic, and breast cancers. Its product candidates also include stem cell therapies for cancer, which is in pre-clinical-stage.

Officers and directors

Andrew Gengos President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Anthony J. Gringeri Ph.D. Senior Vice President - Strategic Resources
Age: 62
Bio & Compensation  - Reuters
David E. Fractor Principal Accounting Officer, Vice President - Finance
Age: 55
Bio & Compensation  - Reuters
Rahul Singhvi Lead Independent Director
Age: 50
Bio & Compensation  - Reuters
John S. Yu M.D. Director
Age: 51
Bio & Compensation  - Reuters
Gregg A. Lapointe CPA Independent Director
Age: 56
Bio & Compensation  - Reuters
Mark A. Schlossberg Esq. Independent Director
Age: 54
Bio & Compensation  - Reuters
Gary S. Titus Independent Director
Age: 55
Bio & Compensation  - Reuters